Peptide-receptor radionuclide therapy of ¹⁷⁷Lu-DOTA-TATE progressive medullary thyroid cancer. foreign and domestic experience: a review

Introduction: Medullary thyroid cancer is a rare neuroendocrine tumor and occurs in hereditary and sporadic forms. As in other NETs, somatostatin receptors are overexpressed in the cell membrane in more than 75% of cases of medullary thyroid cancer. Therefore, in recent years, radioactively labeled somatostatin analogues have been considered not only for assessing the prevalence of the tumor process, but also for the treatment of this disease.

Objective: Аnalyze the global and domestic experience of using peptide receptor radionuclide therapy ¹⁷⁷Lu-DOTA-TATE in the treatment of patients with advanced medullary thyroid cancer.

Materials and methods: In the period from 01.03.2024 to 01.08.2025, data from more than 30 foreign literature sources relevant to this topic were analyzed in the Pubmed, Google Scholar and eLibrary databases.

Results: Of the studies confirm the feasibility of introducing ¹⁷⁷Lu-DOTA-TATE PRRT into clinical practice for certain groups of patients.

Discussion: PRRT ¹⁷⁷Lu-DOTA-TATE allows achieving disease control in most patients: it can maintain disease stabilization with a small number of side effects, and in some cases patients manage to achieve a complete response (CR) and partial response (PR) to treatment.

Conclusion: In order to introduce PRRT ¹⁷⁷Lu-DOTA-TATE into the broad clinical practice of treating metastatic prostate cancer, additional multicenter randomized controlled clinical trials are needed, as well as exploring the possibility of combining PRRT ¹⁷⁷Lu-DOTA-TATE with other treatment options such as ITC therapy, chemotherapy and immunotherapy, as well as radionuclide therapy with other RFLPs.

1. Wells S.A., Asa S.L., Dralle H. et al. American Thyroid Association guidelines task force on medullary thyroid carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma // Thyroid. 2015. Vol. 25, No. 6. P. 567–610. http://doi.org/10.1089/thy.2014.0335.

2. Wells S.A.Jr, Robinson B.G., Gagel R.F. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double blind phase III trial // J. Clin. Oncol. 2012. Vol. 30, No. 2. P. 134–141. http://doi.org/10.1200/JCO.2011.35.5040.

3. Elisei R., Schlumberger M.J., Müller S.P. et al. Cabozantinib in progressive medullary thyroid cancer // J. Clin. Oncol. 2013. Vol. 31, No. 29. P. 3639–3646. http://doi.org/10.1200/JCO.2012.48.4659.

4. Borodavina E.V., Kutukova S.I., Kekeeva Т.V., Isaev Р.A. Selpercatinib in the treatment of medullary and radioiodine-refractory differentiated thyroid cancer with RET mutation (literature review). Head and Neck Tumors (HNT), 2025, Vol. 15, No. 1, рр. 74–88 (In Russ.). https://doi.org/10.17650/2222-1468-2025-15-1-74-88.

5. Brose M.S., Bible K.C., Chow L.Q.M. et al. Management of treatment related toxicities in advanced medullary thyroid cancer // Cancer Treat. Rev. 2018. Vol. 66. P. 64–73. http://doi.org/10.1016/j.ctrv.2018.04.007.

6. Wirth L., Subbiah V., Worden F. et al. Updated safety and effiсасу оf selpercatinib in patients with RET fusion-positive thyroid cancer: data from LIBRETTO-001 // Annals of Oncology. 2023. Vol. 34. P. S1147–S1148. http://doi.org/10.1016/j.annonc.2023.09.1085.

7. Wirth L.J., Brose M.S., Subbiah V. et al. Durability of response with selpercatinib in patients with RET activated thyroid cancer: long-term safety and efficacy from LIBRETTO 001 // J. Clin. Oncol. 2024. Vol. 42, No. 27. P. 3187–3195. http://doi.org/10.1200/JCO.23.02503.

8. Salavati A., Puranik A., Kulkarni H.R. et al. Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues // Semin. Nucl. Med. 2016. Vol. 46, No. 3. P. 215–224. http://doi.org/10.1053/j.semnuclmed.2016.01.010.

9. Krenning E.P., Bakker W.H., Breeman W.A. et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin // Lancet. 1989. Vol. 1, No. 8632. P. 242–244. http://doi.org/10.1016/s0140-6736(89)91258-0.

10. Strosberg J., El-Haddad G., Wolin E. et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors // N. Engl. J. Med. 2017. Vol. 376, No. 2. P. 125– 135. http://doi.org/10.1056/NEJMoa1607427.

11. Hope T.A., Calais J., Zhang L. et al. 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTA-TATE PET: Impact on Krenning Scores and Effect of Tumor Burden // J. Nucl. Med. 2019. Vol. 60, No. 9. P. 1266–1269. http://doi.org/10.2967/jnumed.118.223016.

12. Hofman M.S., Lau W.F., Hicks R.J. Somatostatin receptor imaging with 68Ga DOTA-TATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation // Radiographics. 2015. Vol. 35, No. 2. P. 500–16. http://doi.org/10.1148/rg.352140164.

13. Hope T., Abbott A., Colucci K. et al. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177LuDOTATATE // Nucl Med. 2019. Vol. 60, No. 7. P. 937–943. https://doi.org/10.2967/jnumed.118.230607.

14. Shurinov A.Yu., Krylov V.V., Borodavina E.V., Severskaya N.V. The peptide-receptor radinuclide therapy with radiopharmaceutical 177Lu-DOTA-TATE. Journal of oncology: diagnostic radiology and radiotherapy, 2025, Vol. 8, No. 2, рр. 32–41 (In Russ.). https://doi.org/10.37174/2587-7593-2025-8-2-32-41.

15. Makis W., McCann K., McEwan A.J. Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTA-TATE PRRT: a report of two cases // Clin. Nucl. Med. 2015. Vol. 40, No. 5. P. 408–412. http://doi.org/10.1097/RLU.0000000000000706.

16. Vaisman F., Rosado de Castro P.H., Lopes F.P. et al. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer? // Clin. Nucl. Med. 2015. Vol. 40, No. 2. P. 123–127. http://doi.org/10.1097/RLU.0000000000000628.

17. Beukhof C.M., Brabander T., van Nederveen F.H. et al. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls // BMC Cancer. 2019. Vol. 19, No. 1. P. 325. http://doi.org/10.1186/s12885-019-5540-5.

18. Parghane R.V., Naik C., Talole S. et al. Clinical utility of 177Lu-DOTA-TATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity // Head Neck. 2020. Vol. 42, No. 3. P. 401–416. http://doi.org/10.1002/hed.26024.

19. Dadgar H., Jafari E., Ahmadzadehfar H. et al. Feasibility and therapeutic potential of the 68Ga/177Lu-DOTA-TATE theranostic pair in patients with metastatic medullary thyroid carcinoma // Ann. Endocrinol. (Paris). 2023. Vol. 84, No. 1. P. 45–51. http://doi.org/10.1016/j.ando.2022.08.001.

20. Tuncel M., Kılıçkap S., Süslü N. Clinical impact of 68Ga-DOTA-TATE PET-CT imaging in patients with medullary thyroid cancer // Ann. Nucl. Med. 2020. Vol. 34, No. 9. P. 663–674.

21. Maghsoomi Z., Emami Z., Malboosbaf R. et al. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review // BMC Cancer. 2021. Vol. 21, No. 1. P. 579. http://doi.org/10.1186/s12885-021-08257-x.